Reviewing Microbot Medical (NASDAQ:MBOT) and Nemaura Medical (NASDAQ:NMRD)

Microbot Medical (NASDAQ:MBOT) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 5.4% of Microbot Medical shares are owned by insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Microbot Medical and Nemaura Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$10.74 million	($0.80)	-2.08
Nemaura Medical	$3,017.00	2.67	-$14.14 million	($0.39)	0.00

Microbot Medical has higher earnings, but lower revenue than Nemaura Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Microbot Medical has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Microbot Medical and Nemaura Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	0	0	1	0	3.00
Nemaura Medical	0	0	0	0	0.00

Microbot Medical currently has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Microbot Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Microbot Medical is more favorable than Nemaura Medical.

Profitability

This table compares Microbot Medical and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-218.30%	-158.17%
Nemaura Medical	N/A	N/A	N/A

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.